Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 17/20 | 0.53 |
| ▸ | PGR | P06401 | 10/20 | 0.53 |
| ▸ | AR | P10275 | 4/20 | 0.52 |
| ▸ | MMP12 | P39900 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291262 | 0.83 | NR3C2 (0.70) | NR3C2PGRAR | |
| SCHEMBL4287089 | 0.83 | NR3C2 (0.68) | NR3C2PGRAR | |
| SCHEMBL3488984 | 0.81 | NR3C2 (0.76) | NR3C2PGRAR | |
| SCHEMBL4299978 | 0.79 | NR3C2 (0.60) | NR3C2PGRAR | |
| SCHEMBL4295560 | 0.79 | NR3C2 (0.66) | NR3C2PGRARMMP12NR3C1 | |
| SCHEMBL4286898 | 0.76 | NR3C2 (0.67) | NR3C2PGRARMMP12NR3C1 | |
| SCHEMBL4296087 | 0.72 | NR3C2 (0.77) | NR3C2PGRARMMP12KDM4E | |
| SCHEMBL4297101 | 0.72 | NR3C2 (0.76) | NR3C2PGRAR | |
| SCHEMBL4298131 | 0.71 | NR3C2 (0.92) | NR3C2PGRAR | |
| SCHEMBL4302163 | 0.71 | NR3C2 (0.74) | NR3C2PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | NR3C2, NR3C1, MC2R | NR3C2 1/4885PGR 408/4885AR 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.